Last update Dec. 30, 2022

Ibandronate Sodium

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

It is an aminobisphosphonate that, like other bisphosphonates, inhibits bone resorption. It is used to treat severe hypercalcemia and osteolytic bone lesions associated with malignant neoplasms and in the prevention and treatment of postmenopausal osteoporosis. It is administered by slow intravenous infusion every day or every 3 to 4 weeks depending on the disease.

A latest update no published data were found on excretion in the breast milk.

Most bisphosphonates are acidic compounds that achieve low plasma concentration. Both features make it unlikely excretion into the milk in clinically significant amount.

Intestinal absorption of bisphosphonates is very low even during fasting and is considered negligible in the presence of milk due to formation with the calcium of non absorbable compounds.

Among bisphosponate preparations, Tiludronate and Zoledronate have the longest half-lives period of elimination and thus they are the less indicated to take while breastfeeding.

Until more data about this drug regarding breastfeeding is available, safer known alternatives (pamidronate) should be of choice, especially in the neonatal period and in case of prematurity.


Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Ibandronate Sodium is also known as

Ibandronate Sodium in other languages or writings:


Ibandronate Sodium belongs to this group or family:


Main tradenames from several countries containing Ibandronate Sodium in its composition:


Variable Value Unit
Oral Bioavail. 0.6 %
Molecular weight 359 daltons
Protein Binding 85.7 - 99.5 %
VD 1.3 - 5.3 l/Kg
Tmax 0.5 - 2 hours
5 - 60 hours


  1. Green SB, Pappas AL. Effects of maternal bisphosphonate use on fetal and neonatal outcomes. Am J Health Syst Pharm. 2014 Abstract
  2. Stathopoulos IP, Liakou CG, Katsalira A, Trovas G, Lyritis GG, Papaioannou NA, Tournis S. The use of bisphosphonates in women prior to or during pregnancy and lactation. Hormones (Athens). 2011 Abstract Full text (link to original source) Full text (in our servers)
  3. Hassen-Zrour S, Korbâa W, Béjia I, Saidani Z, Bergaoui N. Maternal and fetal outcome after long-term bisphosphonate exposure before conception. Osteoporos Int. 2010 Abstract
  4. Djokanovic N, Klieger-Grossmann C, Koren G. Does treatment with bisphosphonates endanger the human pregnancy? J Obstet Gynaecol Can. 2008 Abstract
  5. French AE, Kaplan N, Lishner M, Koren G. Taking bisphosphonates during pregnancy. Can Fam Physician. 2003 Abstract Full text (link to original source) Full text (in our servers)

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM